Found 456 results in Expert Content

Micronization, the process of reducing the size of active pharmaceutical ingredient (API) particles to micrometer scale, plays a critical role in various pharmaceutical applications and analyzing micronized particles is essential to ensure their quality and performance.

Summary: Softgels are ideal for LBF delivery and are compatible with various formulations. Innovations like delayed release and plant-based capsules enhance drug delivery. LBFs with a Quality-by-Design approach offer an efficient route to market for complex drugs.

Summary: Originally published in Inhalation magazine, this article discusses how nasal powder formulations represent a significant stride in drug delivery innovation. With drug developers and approvers evolving to address the unique considerations of nasal drug delivery, nasal powders offer a robust and adaptable platform in the pharmaceutical landscape.

Summary: Catalent President and CEO Alessandro Maselli sits down with Endpoints News founder John Carroll to discuss the evolving role of CDMOs and what’s next for Catalent as it progresses with its shift from public to private ownership under its previously announced transaction with Novo Holdings.

Learn how softgel capsules have advanced drug delivery by encapsulating a variety of active pharmaceutical ingredients (APIs).

Summary: In this interview with Pharmtech, Karunakar Sukuru, Global Vice President, Rx Product Development, Pharma and Consumer Health, Catalent shares his thoughts on the key benefits of Lipid based formulations (LBF.)

Summary: This executive summary showcases examples of real-life tactical and operational decisions involved in the integrated approach to drug development.

Summary: In this webinar, industry experts will discuss how a manufacturing on-demand strategy can enhance your clinical development and improve drug supply utilization.

Summary: In this article, Dr. Alan Watts, Director of Innovation & Partnerships for Orally Inhaled Products at Catalent, and Michael Tauber, Senior Director of Pharmaceutical Development at Acorda Therapeutics discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS can be used to successfully bring new inhaled therapies to market.

Summary: This article discusses how to successfully develop and manufacture spray-dried pulmonary and nasal powders and how a CDMO partner plays an integral role in the successful development and commercialization of inhalation products.